The Smoking Cessation drugs in development market research report provides comprehensive information on the therapeutics under development for Smoking Cessation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Smoking Cessation. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Smoking Cessation and features dormant and discontinued products.
GlobalData tracks 39 drugs in development for Smoking Cessation by 37 companies/universities/institutes. The top development phase for Smoking Cessation is preclinical with 18 drugs in that stage. The Smoking Cessation pipeline has 34 drugs in development by companies and five by universities/ institutes. Some of the companies in the Smoking Cessation pipeline products market are: Astraea Therapeutics, Omeros and Incannex Healthcare.
The key targets in the Smoking Cessation pipeline products market include 5-Hydroxytryptamine Receptor 2A, Cannabinoid Receptor 2, and Cannabinoid Receptor 1.
The key mechanisms of action in the Smoking Cessation pipeline product include 5-Hydroxytryptamine Receptor 2A Agonist with three drugs in Phase II. The Smoking Cessation pipeline products include eight routes of administration with the top ROA being Oral and five key molecule types in the Smoking Cessation pipeline products market including Small Molecule, and Vaccine.
Smoking Cessation overview
Smoking is addictive; smokers experience an uncontrollable dependence on cigarettes, and stopping can cause severe mental, emotional, or physical reactions. People addicted to smoking develop a tolerance to nicotine. Nicotine acts on acetylcholine receptors, causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body are disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. Symptoms include anger, depression, weight gain, headaches, and dizziness. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patches or nicotine chewing gum.
For a complete picture of Smoking Cessation’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
